AGTC to Present at Upcoming Conferences
Alliance for Regenerative Medicine (ARM)'sCell & Gene Meeting on the Mesa— Carlsbad, California( October 2-4, 2019)
AGTC President & Chief Executive Officer
Sue Washerwill deliver a company presentation at 5:15 p.m. PTon Wednesday, October 2, 2019. A live video webcast of the presentation will be accessible by visiting https://www.meetingonthemesa.com/webcast/.
- Chardan 3rd Annual
Genetic Medicines Conference- New York( October 7-8, 2019)
AGTC Chief Medical Officer
Theresa Heahand Chief Business Officer Stephen Potterwill participate in a fire-side chat at 11:30 a.m. ETon Tuesday, October 8, 2019. A live audio webcast of the presentation at the Chardan conference can be accessed by visiting http://ir.agtc.com/events-and-presentations. A replay will be available on the company's website following the event.
AGTC is a clinical-stage biotechnology company that uses a proprietary gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. Its initial focus is in the field of ophthalmology, where it has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 & ACHM CNGA3). In addition to its clinical trials, AGTC has preclinical programs in optogenetics, adrenoleukodystrophy (ALD), which is a disease of the central nervous system (CNS) and other ophthalmology and otology indications. The optogenetics program is being developed in collaboration with Bionic Sight. AGTC has a significant intellectual property portfolio and extensive expertise in the design of gene therapy products including capsids, promoters and expression cassettes, as well as expertise in the formulation, manufacture and physical delivery of gene therapy products.
Chief Financial Officer
T: (617) 843-5728
Chief Business Officer
T: (617) 413-2754
Source: Applied Genetic Technologies Corporation